Cargando…
Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives
Mesenchymal stem cells (MSCs) are currently studied and used in numerous clinical trials. Nevertheless, some concerns have been raised regarding the safety of these infusions and the thrombogenic risk they induce. MSCs express procoagulant activity (PCA) linked to the expression of tissue factor (TF...
Autores principales: | Coppin, Louise, Sokal, Etienne, Stéphenne, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829440/ https://www.ncbi.nlm.nih.gov/pubmed/31569696 http://dx.doi.org/10.3390/cells8101160 |
Ejemplares similares
-
Clinical Protocol to Prevent Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based Therapies
por: Coppin, Louise, et al.
Publicado: (2019) -
Infusion-related thrombogenesis by liver-derived mesenchymal stem cells controlled by anticoagulant drugs in 11 patients with liver-based metabolic disorders
por: Coppin, Louise C. F., et al.
Publicado: (2020) -
Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective
por: Gupta, Ashim, et al.
Publicado: (2020) -
Everolimus is Safe as a Second-/Third-Line Therapy in Pediatric Autoimmune Hepatitis
por: Jannone, Giulia, et al.
Publicado: (2022) -
Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity
por: Stephenne, Xavier, et al.
Publicado: (2012)